株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

薬物検査:各種技術と世界の市場

Drug Testing: Technologies and Global Markets

発行 BCC Research 商品コード 325569
出版日 ページ情報 英文 135 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.37円で換算しております。
Back to Top
薬物検査:各種技術と世界の市場 Drug Testing: Technologies and Global Markets
出版日: 2017年05月25日 ページ情報: 英文 135 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界の薬物検査の市場は2016年から2021年にかけて4.5%のCAGR (年間複合成長率) で推移し、2016年の約30億ドルから、2021年には31億ドルの規模に成長すると予測されています。

当レポートでは、世界の薬物検査の市場を調査し、市場および技術の概要、主要国における薬物関連法規制、国際的な薬物密売・不正利用の動向、サンプルタイプ別の市場規模の推移と予測、産業構造、競合環境、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第3章 市場および技術の背景

  • シングルパラメーター vs マルチパラメーター
  • DOAスクリーニング
  • 確認検査
  • 尿検査
  • その他の検査法
    • 血液検査
    • 口腔液検査
    • 唾液検査
    • 汗検査
    • 毛髪検査
  • 検査場所
    • ラボベースDAT
    • POC DAT
  • オンサイト検査 vs ラボ検査
  • ラボ検査のサンプルタイプ
    • 尿検査
    • 毛髪検査
    • 口腔液/唾液検査
    • 血液検査
    • 汗検査
    • 眼反射
  • 検出時間
  • 薬物検査の偽装
  • サンプルの有効性検査
  • 偽陽性・偽陰性
  • 検査技術
  • 免疫測定
    • EIA
    • ELISA
    • EMIT
    • FPIA
    • RIA
    • クロマトグラフィ
    • 眼反射測定

第4章 薬物関連法規制:主要国別

第5章 市場概要

  • 薬物乱用検査
  • 国際的な薬物密売・不正利用の動向:薬物タイプ別
    • アンフェタミン系覚醒剤
    • 大麻
    • コカ/コカイン
    • アヘン/ヘロイン
  • 国際的な薬物密売・不正利用の動向:地域別

第6章 世界の薬物乱用検査市場:サンプルタイプ別

  • 薬物乱用検査:売上
    • 尿
    • 血液
    • 口腔液
    • 毛髪
    • その他

第7章 産業構造

  • 地域分析
  • 総市場の予測:薬物乱用検査・薬物モニタリング
    • 成長動向:ラボ検査・オンサイト検査
  • 競合分析
    • 主要企業

第8章 特許分析

第9章 企業プロファイル

BCC Researchについて

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHM013G

Report Highlights

The global drug of abuse (DOA) testing market reached nearly $3.0 billion in 2016. This market is estimated to grow at a compound annual growth rate (CAGR) of 4.5% to reach nearly $3.9 billion by 2022 from $3.1 billion in 2017.

Report Includes:

  • An overview of the global market for drug testing technologies.
  • Analyses of global market trends, with data from 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022
  • An overview of drug abuse trends in terms of various geographic regions as well as drug classes.
  • Information on leading players in the market and their key products.
  • Analysis of leading companies in the field and their successful strategies.

Report Scope

This report contains:

  • An overview of drug abuse trends in terms of various geographic regions as well as drug classes.
  • Drug abuse statistics in key regions.
  • Analysis of regulatory environments in North, South and Central America, Europe, and Asia-Pacific, and country-wise summaries of national legislation and policies.
  • Drug of abuse testing markets with respect to testing approaches and sample matrices.
  • Technology trends in the drug of abuse testing market.
  • Leading players in the market and their key products.
  • Sales projections through 2022 for drug of abuse testing markets by sample matrix and geographic regions.
  • Analysis of leading companies and their successful strategies.

Analyst Credentials

Jon Evans has been involved in business development and research for the medical industry since 1984. Evans' career includes four years as a diagnostic systems sales representative and more than 15 years in market research and strategy analysis with Fortune 500 clients. He has developed expertise in assessing the unique business development challenges facing firms in the medical industry and designing strategies to optimize market performance. Mr. Evans received a B.S. in biology from Rutgers University in 1983, and an MBA in business analysis from San Francisco State University in 1989.

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing the Study
  • Intended Audience
  • Scope of Report
  • Methodology
  • Information Sources
  • Geographic Breakdown
  • Analyst's Credentials
  • Related BCC Research Reports
  • Executive Summary

Chapter 3: Market and Technology Background

  • Single- Vs. Multi-Parameter Test
  • DOA Screening
  • Confirmation Testing
  • Urine Tests
  • Other Testing Methods
    • Blood Testing
    • Oral Fluid Testing
    • Saliva Testing
    • Sweat Testing
    • Hair Testing
  • Testing Locations
    • Laboratory-Based DAT
  • Point of Care DATS
  • Onsite Testing Vs Laboratory Testing
  • Sample Types for Laboratory Testing
    • Urine Testing
    • Hair Testing
    • Saliva/Oral Fluid Testing
    • Blood Testing
    • Sweat Testing
    • Eye Reflex
  • Detection Period
  • Fooling a Drug Test
    • Fooling Urine Testing
    • Fooling Hair Testing
    • Fooling Saliva Testing
  • Sample Validity Tests
  • False Positives and False Negatives
    • False Positives
    • False Negatives
    • Drug Clearance and Testing Window
  • Testing Technologies
    • Immunoassays
    • Enzyme Immunoassay (EIA)
    • Enzyme-Linked Immunosorbent Assay (ELISA)
    • Enzyme Multiplied Immunoassay Technology (EMIT)
    • Fluorescence Polarization Immunoassay (FPIA)
    • Radioimmunoassay (RIA)
    • Chromatography
    • Eye Reflex Measurements

Chapter 4: Government Regulations: Drug Trafficking and Drug Abuse Testing

  • North America
    • Canada
    • Mexico
    • U.S.
    • State Marijuana Legalization
    • U.S. Department of Transportation
    • Drug Testing in the Military
    • Drug Testing for Welfare Recipients and Public Assistance
    • Drug Testing for Individuals Convicted of Drug Felonies
  • South America
    • Bolivia
    • Brazil
    • Colombia
    • Ecuador
    • Guyana
    • Paraguay
    • Peru
  • Central America and the Caribbean
    • Costa Rica
    • Cuba
    • El Salvador
    • Guatemala
    • Haiti
    • Jamaica
    • Nicaragua
    • Panama
    • Honduras
    • The Bahamas
    • The Netherlands Antilles
    • Trinidad and Tobago
  • Europe
    • Bosnia and Herzegovina
    • Denmark
    • France
    • Germany
    • Italy
    • Latvia
    • Norway
    • Romania
    • Sweden
    • Switzerland
    • The Netherlands
    • The United Kingdom
  • Asia-Pacific
    • Australia
    • Bangladesh
    • Bhutan
    • Cambodia
    • Hong Kong
    • India
    • Japan
    • Maldives
    • Myanmar
    • Nepal
    • New Zealand
    • Singapore
    • South Korea
    • Sri Lanka
    • Taiwan
    • Thailand
    • Vietnam

Chapter 5: Overview of Drug Abuse Testing

  • Drug Abuse Testing
  • International Drug Trafficking and Illicit Drug Use Trends by Drug Type
    • Amphetamine-Type Stimulants Market
    • Cannabis Market
    • Coca/Cocaine Market
    • Opium/Heroin Market
  • International Drug Trafficking and Illicit Drug Use Trends by Geographic Region
    • Africa
    • Central America and Caribbean
    • North America
    • South America
    • East and Southeast Asia
    • South Asia
    • West Asia
  • Europe
  • Oceania
  • U.S. DOA Statistics
    • National Household Survey on Drug Abuse: SAMHSA U.S.

Chapter 6: Global Drugs of Abuse Testing Market by Sample Type

  • DOA Testing Sales
  • Global Sales of DOA Testing by Urine
  • Global Sales of DOA Testing by Blood
  • Global Sales of DOA Testing by Oral Fluid
  • Global Sales of DOA Testing by Hair
  • Global Sales of DOA Testing by Sweat
  • Global Sales of DOA Testing by Other Sample Types

Chapter 7: Global Industry Structure

  • Regional Analysis
  • Total DOA Testing and Drug Monitoring Markets and Forecasts
    • Growth Trends-Laboratory-based and Onsite DOA Testing Markets
  • Competitive Analysis
    • Key Market Players in the DOA Testing Markets and Their Products
  • Laboratory-based DOA Testing Market Segment
  • Onsite Testing Market Segment for DOA
  • Common DOA and Most Popular Devices Used for Testing Them
  • Companies in the Oral Fluid, Hair and Sweat Testing Segments for DOA

Chapter 8: Patent Analysis

Chapter 9: Company Profiles

About BCC Research

  • About BCC Research
  • BCC Library Access
  • BCC Custom Research

List of Tables

  • Summary Table: Global DOA Testing Market Forecast, by Test Type, Through 2022 ($ Millions)
    • Table 1: Advantages and Disadvantages of Point of Care Testing
    • Table 2: Major Advantages and Disadvantages of Onsite Testing
    • Table 3: Detection Periods for Various Types of Drug Testing
    • Table 4: Common Parameters Tested for Urine Specimen Validity
    • Table 5: Some of the Commercial/Common Adulterants Used in Fooling Urine Tests and Their Effects
    • Table 6: Urine Sample Validity Test Methods
    • Table 7: Cross Reactants That Can Lead to False Positives in DOA Testing
    • Table 8: Clearance Rates for Common DOA
    • Table 9: U.S. Drug Testing Legislations by State, 2017
    • Table 10: Selected State Marijuana Legalization, 2016
    • Table 11: Drug Testing Legislation by European Country
    • Table 12: Number of Illicit Drug Users Globally, 2015 (Millions)
    • Table 13: Number of Drug-Related Deaths, Mortality Rates per Million Persons Aged 15-64 Years and Ranking of Drugs as Primary Cause of Death (2014 or Latest Year Available), 2016
    • Table 14: Estimated Number of Drug-Related Deaths and Mortality Rates per Million Persons Aged 15-64 Years, 2014
    • Table 15: Annual Prevalence by Region, 2016
    • Table 16: U.S. DOA Seizures, 2014
    • Table 17: Annual Prevalence of Opioid Use as a Percentage of the Population Aged 15-64, 2015 (%)
    • Table 18: Annual Prevalence of Cocaine Use as a Percentage of the Population Aged 15-64, 2015 (%)
    • Table 19: Annual Prevalence of Cannabis Use as a Percentage of the Population Aged 15-64, 2015 (%)
    • Table 20: Annual Prevalence of ATS Use as a Percentage of the Population Aged 15-64, 2015 (%)
    • Table 21: Annual Prevalence of Ecstasy Use as a Percentage of the Population Aged 15-64, 2015 (%)
    • Table 22: Drug Abuse Statistics in the U.S. by Drug Type (12 Yrs and Older), 2014 and 2015 (Thousands)
    • Table 23: U.S. Types of Illicit Drug Use in Lifetime, Past Year, and Past Month Among Persons Aged 18 or Older: Percentages, 2014 and 2015 (%)
    • Table 24: U.S. Illicit Drug Use in Lifetime, Past Year, and Past Month, by Detailed Age Category: Percentages, 2014 and 2015 (%)
    • Table 25: U.S. Marijuana Use in Lifetime, Past Year, and Past Month, by Detailed Age Category: Percentages, 2014 and 2015 (%)
    • Table 26: Global Sales Contribution for DOA Testing, by Sample Type, Through 2022 (%)
    • Table 27: Global Sales Forecast for DOA Testing, by Sample Type, Through 2022 ($ Millions)
    • Table 28: Global Sales Forecast for DOA Testing by Urine, Through 2022 ($ Millions)
    • Table 29: Global Sales Forecast for DOA Testing by Urine: Laboratory-based versus Onsite, through 2022 ($ Millions)
    • Table 30: Global Sales Forecast for DOA Testing, by Blood, Through 2022 ($ Millions)
    • Table 31: Global Sales Forecast for DOA Testing, by Oral Fluid, Through 2022 ($ Millions)
    • Table 32: Global Sales Forecast for DOA Testing by Oral Fluid: Laboratory-based versus Onsite, Through 2022 ($ Millions)
    • Table 33: Global Sales Forecast for DOA Testing, by Hair, Through 2022 ($ Millions)
    • Table 34: Global Sales Forecast for DOA Testing, by Sweat, Through 2022 ($ Millions)
    • Table 35: Global Sales Forecast for DOA Testing, by Other Sample Types, Through 2022 ($ Millions)
    • Table 36: Global DOA Testing Market Forecast, by Region, Through 2022 ($ Millions)
    • Table 37: DOA Testing Market Forecast for Laboratory-based DOA Testing, Through 2022 ($ Millions)
    • Table 38: DOA Testing Market Forecast for Onsite DOA Testing, Through 2022 ($ Millions)
    • Table 39: Most Notable Mergers and Acquisitions in the DOA Testing Markets, 2000-2016
    • Table 40: Major Companies and Their Products in the DOA Testing Market
    • Table 41: Companies Offering Laboratory-based DOA Testing Products
    • Table 42: Main Onsite DOA Testing Market Players and Their Products
    • Table 43: Common DOA and Popular Urine Drug Screening Products
    • Table 44: Key Market Players Offering DOA Testing Products on Oral Fluid, Hair and Sweat Sample Types
    • Table 45: Selected U.S. Patents Granted for DOA Testing, 2007-2017

List of Figures

  • Summary Figure: Global Drugs of Abuse Testing Market Forecast, by Test Matrix, 2016-2022 ($ Millions)
  • Figure 1: U.S. DOA Seizures, 2014
  • Figure 2: Global Sales Forecast for DOA Testing, by Sample Type, 2016-2022 ($ Millions)
  • Figure 3: Global Sales Forecast for Drugs of Abuse Testing by Urine, 2016-2022 ($ Millions)
  • Figure 4: Global Sales Forecast for Drugs of Abuse Testing by Urine: Laboratory-based versus Onsite, 2016-2022 ($ Millions)
  • Figure 5: Global Sales Forecast for Drugs of Abuse Testing, by Blood, 2016-2022 ($ Millions)
  • Figure 6: Global Sales Forecast for Drugs of Abuse Testing, by Oral Fluid, 2016-2022 ($ Millions)
  • Figure 7: Global Sales Forecast for Drugs of Abuse Testing, by Oral Fluid: Laboratory-based versus Onsite, 2016-2022 ($ Millions)
  • Figure 8: Global Sales Forecast for Drugs of Abuse Testing, by Hair, 2016-2022 ($ Millions)
  • Figure 9: Global Sales Forecast for Drugs of Abuse Testing by Sweat, 2016-2022 ($ Millions)
  • Figure 10: Global Sales Forecast for DOA Testing, by Other Sample Types, 2016-2022 ($ Millions)
  • Figure 11: Drugs of Abuse Testing Markets, by Geographic Region, 2017 (%)
Back to Top